Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of
lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate
Alzheimer's disease (AD).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Pfizer Wyeth is now a wholly owned subsidiary of Pfizer